secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001104659-26-043227
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio completes sale of six product franchises to Cosette for $35M cash plus up to $35M contingent payments
--------------------------------------------------------------------------------

- Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.
- Upfront cash $35M; potential milestones up to $32M (SYMPAZAN, INDOCIN, OTREXUP) and SPRIX earn-out (quality approval $1M, 8% gross profits through 2027, $2M if 2027 net sales >$7M).
- Pro forma continuing ops: 2025 net loss ~$31.3M (historical $30.4M); 2024 net loss ~$27.5M (historical $21.6M).
- Estimated transaction costs ~$1.9M; estimated gain on disposal ~$16M.
- Company also divested Assertio Therapeutics in May 2025; results removed from continuing ops in pro forma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/0001104659-26-043227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000110465926043227/tm2611405d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-043227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer